NCT04470622 - Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

April 9, 2021

Study Completion Date

June 3, 2021

Conditions

COVID-19

Interventions

DRUG

Aprepitant injectable emulsion

Aprepitant injectable emulsion, once daily (QD) for 14 days.

DRUG

Saline Placebo

Saline Placebo, once daily (QD) for 14 days.

Trial Locations (3)

Helen Keller Hospital, Sheffield

University of California, Irvine Medical Center, Orange

Yale University School of Medicine, New Haven